



Press Release

Monday, April 19, 2010

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

STRIDES ARCOLAB ANNOUNCES USFDA APPROVAL FOR MESNA INJECTION

TOTAL APPROVALS IN STERILE SPACE AT 21

Strides Arcolab Limited (Strides) today announced receipt of ANDA approval for its Abbreviated New Drug Application (ANDA) to market Mesna injection (Mesna), a prophylactic agent used to reduce the incidence of hemorrhagic cystitis caused by Ifosfamide chemotherapy. Mesna will be available in 1 mg per 10 mL multi-dose vials, offered in single packs and in packs of ten. According to 2009 IMS data, the U.S. market for Mesna approximated \$12 million. This is expected to be launched shortly .

Ravi Seth, Chief Executive Officer – International Operations of Strides stated: “This is our second product approval in this month and the fifth for the partnership with Sagent. We are excited by the growth prospects of our business in USA “

Mesna is the fifth product being launched under the partnership between Strides and Sagent Pharmaceuticals wherein Strides is developing and supplying more than 25 injectable products for the U.S. market which will be marketed by Sagent .

About Mesna Injection

Mesna is the generic equivalent of Baxter International’s Mesnex[®] and is indicated as a prophylactic agent in reducing the incidence of Ifosfamide-induced hemorrhagic cystitis.

About Strides Arcolab Limited:

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries, including its joint venture with Aspen in India and has a marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at the company's website at www.stridesarco.com.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence™ and learn more about Sagent, please visit www.SagentPharma.com.

For further information, please contact:

Mr. Ravi Seth CEO – International Operations Ph: +91 80 6658 0121	Mr. Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: maheshn@corvoshandwick.co.in
Mr. N Kannan, Company Secretary (Investors) Tel : +91 80 6658 0751	Ms. Kasturi Wasmatar, Corporate Voice/ Weber Shandwick Mobile: 99167 28393 Email: kasturi@corvoshandwick.co.in
Ms. Melissa Arulappan (Media) Tel: +91 98450 22389	